Comparison Between Neutrophil-Lymphocyte Ratio and Systemic Immune-Inflammation Index as Predictors of One-Year Survival in Patients with Untreated Advanced Hepatocellular Carcinoma

被引:7
作者
Hasan, Irsan [1 ]
Lutfie, Lutfie [2 ]
Rinaldi, Ikhwan [3 ]
Kurniawan, Juferdy [1 ]
Loho, Imelda Maria [4 ]
机构
[1] Univ Indonesia, Fac Med, Dept Internal Med, Div Hepatobiliary,Cipto Mangunkusumo Natl Cent Ge, Jakarta, Indonesia
[2] Univ Indonesia, Fac Med, Dept Internal Med, Cipto Mangunkusumo Natl Cent Gen Hosp, Jakarta, Indonesia
[3] Univ Indonesia, Fac Med, Dept Internal Med, Div Med Oncol Hematol,Cipto Mangunkusumo Natl Cen, Jakarta, Indonesia
[4] Univ Indonesia, Fac Med, Div Gastroenterol & Hepatol, Dept Internal Med,Dharmais Natl Canc Ctr Hosp, Jakarta, Indonesia
关键词
Hepatocellular carcinoma; Neutrophil-lymphocyte ratio; Systemic immune-inflammation index; One-year survival; PROGNOSTIC VALUE; METAANALYSIS; CANCER;
D O I
10.1007/s12029-021-00796-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Patients with hepatocellular carcinoma (HCC) generally only come for treatment when cancer has reached an advanced stage, with very limited treatment options. There has not been an accurate predictor marker to be able to identify which group of patients may have better survival. This study wanted to analyze the role of the inflammatory status indices as predictors of 1-year survival in patients with advanced HCC who did not undergo therapy. Methods This study has a retrospective cohort design using secondary data on subjects with advanced HCC who did not undergo therapy at Cipto Mangunkusumo Hospital and Dharmais Hospital. The neutrophil-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) were evaluated for their role as predictors of 1-year survival based on the area under receiving operator curve (AUROC). The best optimal cut-off for NLR and SII was decided based on the Youden index, followed by survival analysis based on those cut-offs. Confounding factors were analyzed with multivariate cox regression analysis. Results A total of 196 subjects were included in the data analysis. One-year survival was 6.6%, with a median survival of 56 days (95% CI: 46-67). The NLR had a discriminatory ability based on AUROC of 0.667 (95% CI: 0.536-0.798; p = 0.044), with the optimal cut-off point to differentiate survival was 3.7513. The SII has a discriminatory ability based on AUROC of 0.766 (95% CI: 0.643-0.889; p = 0.001), with the optimal cut-off point to distinguish survival was 954.4782. SII had superiority in discriminatory ability (p = 0.0415). Conclusions The discriminatory ability based on AUROC of SII was better than that of NLR in predicting 1-year survival in patients with advanced HCC who did not undergo therapy.
引用
收藏
页码:135 / 146
页数:12
相关论文
共 22 条
[1]   The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis [J].
Aino, Hajime ;
Sumie, Shuji ;
Niizeki, Takashi ;
Kuromatsu, Ryoko ;
Tajiri, Nobuyoshi ;
Nakano, Masahito ;
Satani, Manabu ;
Okamura, Shusuke ;
Shimose, Shigeo ;
Miyahara, Kensuke ;
Torimura, Takuji .
MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (01) :83-88
[2]   Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis [J].
Aino, Hajime ;
Sumie, Shuji ;
Niizeki, Takashi ;
Kuromatsu, Ryoko ;
Tajiri, Nobuyoshi ;
Nakano, Masahito ;
Satani, Manabu ;
Yamada, Shingo ;
Okamura, Shusuke ;
Shimose, Shigeo ;
Sumie, Hiroaki ;
Torimura, Takuji ;
Sata, Michio .
MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) :393-398
[3]   Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma [J].
Bruix, Jordi ;
Reig, Maria ;
Sherman, Morris .
GASTROENTEROLOGY, 2016, 150 (04) :835-853
[4]   A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepatocellular Carcinoma [J].
Cabibbo, Giuseppe ;
Enea, Marco ;
Attanasio, Massimo ;
Bruix, Jordi ;
Craxi, Antonio ;
Camma, Calogero .
HEPATOLOGY, 2010, 51 (04) :1274-1283
[5]   The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib [J].
Conroy, Guillaume ;
Salleron, Julia ;
Belle, Arthur ;
Bensenane, Mouni ;
Nani, Abdelbasset ;
Ayav, Ahmet ;
Peiffert, Didier ;
Lopez, Anthony ;
Baumann, Cedric ;
Barraud, Helene ;
Bronowicki, Jean-Pierre .
ONCOTARGET, 2017, 8 (56) :95853-95864
[6]   Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib [J].
Gardini, Andrea Casadei ;
Scarpi, Emanuela ;
Faloppi, Luca ;
Scartozzi, Mario ;
Silvestris, Nicola ;
Santini, Daniele ;
de Stefano, Giorgio ;
Marisi, Giorgia ;
Negri, Francesca V. ;
Foschi, Francesco Giuseppe ;
Valgiusti, Martina ;
Ercolani, Giorgio ;
Frassineti, Giovanni Luca .
ONCOTARGET, 2016, 7 (41) :67142-67149
[7]   Prognosis of Untreated Hepatocellular Carcinoma [J].
Giannini, Edoardo G. ;
Farinati, Fabio ;
Ciccarese, Francesca ;
Pecorelli, Anna ;
Rapaccini, Gian Lodovico ;
Di Marco, Mariella ;
Benvegnu, Luisa ;
Caturelli, Eugenio ;
Zoli, Marco ;
Borzio, Franco ;
Chiaramonte, Maria ;
Trevisani, Franco .
HEPATOLOGY, 2015, 61 (01) :184-190
[8]   Comparing Staging Systems for Predicting Prognosis and Survival in Patients with Hepatocellular Carcinoma in Egypt [J].
Gomaa, Asmaa Ibrahim ;
Hashim, Mohamed Saad ;
Waked, Imam .
PLOS ONE, 2014, 9 (03)
[9]   Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma [J].
Hu, Bo ;
Yang, Xin-Rong ;
Xu, Yang ;
Sun, Yun-Fan ;
Sun, Chao ;
Guo, Wei ;
Zhang, Xin ;
Wang, Wei-Min ;
Qiu, Shuang-Jian ;
Zhou, Jian ;
Fan, Jia .
CLINICAL CANCER RESEARCH, 2014, 20 (23) :6212-6222
[10]   Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia [J].
Jasirwan, Chyntia Olivia Maurine ;
Hasan, Irsan ;
Sulaiman, Andri Sanityoso ;
Lesmana, Cosmas Rinaldi A. ;
Kurniawan, Juferdy ;
Kalista, Kemal Fariz ;
Nababan, Saut Horas ;
Gani, Rino Alvani .
CURRENT PROBLEMS IN CANCER, 2020, 44 (01)